Why is GKOS down?
Down 4.2% today, while its medical device peers are up 0.8%; no story names it yet.
Ahead of the market
Up 390% over five years while the S&P 500 rose 67%.
- Revenue grew 17.7% a year against its 3 peers' median of 7.7%;
Down 4.2% today, while its medical device peers are up 0.8%; no story names it yet.
Ahead of the market
Up 390% over five years while the S&P 500 rose 67%.
GKOS's Quality Score fell 2 points on Wed, Nov 18, to 12.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The chart | Stronger than 97% of stocks |
| Latest filing | 8-K, Oct 28 |
TodayNo story names it yet.
Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.
2 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +18.6% on average, higher 4 of 4 times.
Above Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
GKOS is #15 of 87 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 15 |
Share count against a year before: GKOS +3%, HTFL +78%, TFX -6.2%, HAE -4.4%.
Expected to report Tue Feb 16, after the close (in 90 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $211.0M, 58% more than a year ago; a profit of $0.03 a share, from a loss of $0.28.
“Our third quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally, as well as growing contributions of Epioxa®.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Glaucoma | $152M | $155M | $110M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 28)
| Measure | Figure |
|---|---|
| Net sales | $775M to $785M |
Sales grew 18% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 5.1% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | +16.3% | +33.6% | +36.0% |
| Jul 29, 2026 | +11.5% | +4.2% | +5.7% |
| Apr 29, 2026 | +21.0% | +22.8% | +15.7% |
Sales grew in five of the last seven years, to $507M in 2025. It made a profit in one of the eight years.
RSI 59.5, MACD below signal, above both averages. Not scored.
4 insiders sold $25.1M across 12 filings in the last 6 months. No open-market buys on record. The newest:
3 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: GKOS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
GKOS scores 12 today, which Breakaway calls Above Average. It is #15 of 87 in Medical Devices by Quality Score, with 4 of 14 chart checks firing. Up 390% over five years while the S&P 500 rose 67%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
GKOS scores 12 today, which Breakaway calls Above Average (11 to 14). That is #15 of 87 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GKOS's 12.
4 insiders sold $25.1M across 12 filings in the last 6 months. No open-market buys on record. The newest is Gilbert H. Kliman, Director, who sold $633K on Nov 4. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Friday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.